Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT05743595 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Unmethylated Glioblastoma

Interventions

BIOLOGICAL: Personalized Neoantigen DNA vaccine
BIOLOGICAL: Retifanlimab
DEVICE: TDS-IM v 2.0 electroporation device

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]